| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, Lausanne, Switzerland;
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland;
Research Unit, Department of Surgery, University of Basel, Basel, Switzerland;
Multidisciplinary Oncology Center, University Hospital, Lausanne, Switzerland; and
¶
Institute of Molecular Medicine, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom
There is considerable interest in the development of vaccination strategies that would elicit strong tumor-specific CTL responses in cancer patients. One strategy consists of using recombinant viruses encoding amino acid sequences corresponding to natural CTL-defined peptide from tumor Ags as immunogens. However, studies with synthetic tumor antigenic peptides have demonstrated that introduction of single amino acid substitutions may dramatically increase their immunogenicity. In this study we have used a well-defined human melanoma tumor Ag system to test the possibility of translating the immunological potency of synthetic tumor antigenic peptide analogues into recombinant vaccinia viruses carrying constructs with the appropriate nucleotide substitutions. Our results indicate that the use of a mutated minigene construct directing the expression of a modified melanoma tumor Ag leads to improved Ag recognition and, more importantly, to enhanced immunogenicity. Thus, recombinant vaccinia viruses containing mutated minigene sequences may lead to new strategies for the induction of strong tumor-specific CTL responses in cancer patients.
This article has been cited by other articles:
|
|
 |
|
  L. Derre, M. Ferber, C. Touvrey, E. Devevre, V. Zoete, A. Leimgruber, P. Romero, O. Michielin, F. Levy, and D. E. Speiser A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide J. Immunol., December 1, 2007; 179(11): 7635 - 7645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Colombetti, T. Fagerberg, P. Baumgartner, L. Chapatte, D. E. Speiser, N. Rufer, O. Michielin, and F. Levy Impact of Orthologous Melan-A Peptide Immunizations on the Anti-Self Melan-A/HLA-A2 T Cell Cross-Reactivity. J. Immunol., June 1, 2006; 176(11): 6560 - 6567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chapatte, M. Ayyoub, S. Morel, A.-L. Peitrequin, N. Levy, C. Servis, B. J. Van den Eynde, D. Valmori, and F. Levy Processing of Tumor-Associated Antigen by the Proteasomes of Dendritic Cells Controls In vivo T-Cell Responses. Cancer Res., May 15, 2006; 66(10): 5461 - 5468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chapatte, S. Colombetti, J.-C. Cerottini, and F. Levy Efficient Induction of Tumor Antigen-Specific CD8+ Memory T Cells by Recombinant Lentivectors Cancer Res., January 15, 2006; 66(2): 1155 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhou, Y. Luo, M. Mizutani, N. Mizutani, R. A. Reisfeld, and R. Xiang T cell-mediated suppression of angiogenesis results in tumor protective immunity Blood, September 15, 2005; 106(6): 2026 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chapatte, C. Servis, D. Valmori, O. Burlet-Schiltz, J. Dayer, B. Monsarrat, P. Romero, and F. Levy Final Antigenic Melan-A Peptides Produced Directly by the Proteasomes Are Preferentially Selected for Presentation by HLA-A*0201 in Melanoma Cells J. Immunol., November 15, 2004; 173(10): 6033 - 6040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vertuani, A. Sette, J. Sidney, S. Southwood, J. Fikes, E. Keogh, J. A. Lindencrona, G. Ishioka, J. Levitskaya, and R. Kiessling Improved Immunogenicity of an Immunodominant Epitope of the Her-2/neu Protooncogene by Alterations of MHC Contact Residues J. Immunol., March 15, 2004; 172(6): 3501 - 3508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dadaglio, S. Morel, C. Bauche, Z. Moukrim, F. A. Lemonnier, B. J. Van den Eynde, D. Ladant, and C. Leclerc Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes Int. Immunol., December 1, 2003; 15(12): 1423 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Castilleja, D. Carter, C. L. Efferson, N. E. Ward, K. Kawano, B. Fisk, A. P. Kudelka, D. M. Gershenson, J. L. Murray, C. A. O'Brian, et al. Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex J. Immunol., October 1, 2002; 169(7): 3545 - 3554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rimoldi, K. Muehlethaler, S. Salvi, D. Valmori, P. Romero, J.-C. Cerottini, and F. Levy Subcellular Localization of the Melanoma-associated Protein Melan-AMART-1 Influences the Processing of Its HLA-A2-restricted Epitope J. Biol. Chem., November 9, 2001; 276(46): 43189 - 43196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lamikanra, Z.-K. Pan, S. N. Isaacs, T.-C. Wu, and Y. Paterson Regression of Established Human Papillomavirus Type 16 (HPV-16) Immortalized Tumors In Vivo by Vaccinia Viruses Expressing Different Forms of HPV-16 E7 Correlates with Enhanced CD8+ T-Cell Responses That Home to the Tumor Site J. Virol., October 15, 2001; 75(20): 9654 - 9664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sliz, O. Michielin, J.-C. Cerottini, I. Luescher, P. Romero, M. Karplus, and D. C. Wiley Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes J. Immunol., September 15, 2001; 167(6): 3276 - 3284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Peterson, R. J. DiPaolo, O. Kanagawa, and E. R. Unanue Cutting Edge: A Single MHC Anchor Residue Alters the Conformation of a Peptide-MHC Complex Inducing T Cells That Survive Negative Selection J. Immunol., May 15, 2001; 166(10): 5874 - 5877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Chen, P. R. Dunbar, U. Gileadi, E. Jager, S. Gnjatic, Y. Nagata, E. Stockert, D. L. Panicali, Y.-T. Chen, A. Knuth, et al. Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL J. Immunol., July 15, 2000; 165(2): 948 - 955. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
